Phase II and Pharmacologie Study of Docetaxel as Initial Chemotherapy for Metastatic Breast Cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Breast Neoplasms
  • Paclitaxel
  • Taxoids

abstract

  • Docetaxel is active for metastatic breast cancer. Neutropenia and fluid retention are dose-limiting. The AUC did not predict toxicity, but caution is warranted when treating patients with liver dysfunction. An understanding of the pathophysiology of the fluid retention may facilitate prevention. Frequent HSR may warrant prophylactic premedication.

publication date

  • January 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8558221

Additional Document Info

start page

  • 58

end page

  • 65

volume

  • 14

number

  • 1